Cannabinoid and Psychedelic Pharmacology and Drug Development

Cannabinoid and Psychedelic Pharmacology and Drug Development

by Jim Mitchell and Google NotebookLM
ChemistryLife Sciences
Season 3

30 Day Psychedelic Pharmacology Podcast - Expert Level Psychedelic Pharmacology Quiz Podcast

A fascinating and engaging quiz show-style podcast episode about psychedelic pharmacology. The episode features an expert PhD researcher who breaks down complex topics into digestible information, covering key areas such as: - The role of specific receptors like 5HT2A in psychedelic effects - How ketamine affects brain connectivity - The science behind psilocybin's long-lasting effects on neuroplasticity - The future of personalized psychedelic therapies and the ethical considerations in psychedelic research The format combines educational content with entertaining dialogue, making complex pharmacological concepts accessible while maintaining scientific accuracy.
S3 · E33
Jan 30, 2025
31:06

30 Day Psychedelic Pharmacology Podcast - BONUS Spotlight on Sasha and Ann Shulgin and The Alexander Shulgin Foundation and Research Institute

This podcast episode offers an in-depth exploration of Alexander Shulgin's life and contributions to psychedelic research. The discussion covers his groundbreaking work in synthesizing and documenting numerous psychedelic compounds, including MDMA and 2C-B. The episode highlights Shulgin's innovative approach to structure-activity relationships (SAR), his meticulous self-experimentation methods, and his collaboration with his wife Ann Shulgin. The conversation delves into specific compounds like DOM and 5-TOMe, while examining the therapeutic potential of psychedelics and Shulgin's lasting impact on contemporary psychedelic research.
S3 · E34
Jan 30, 2025
25:02

30 Day Psychedelic Pharmacology Podcast - SPECIAL TOPIC Lykos' Modomafetamine Rejection

This podcast episode discusses the FDA's recent rejection of Lykos's MDMA application for PTSD treatment. The conversation explores the FDA's key concerns, including the need for more long-term data and research on drug interactions. The hosts delve into challenges like designing effective placebo trials, the role of personalized medicine, and the importance of understanding individual variations in treatment response. They also examine safety considerations, ethical concerns, and the future potential of MDMA-assisted therapy in mental health care.
S3 · E35
Jan 30, 2025
18:48
Season 4

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 0 Introduction

This introductory episode of a 30-day podcast series explores FDA drug development through the lens of cannabis and psychedelic therapeutics. The conversation covers fundamental concepts including cGMP (current good manufacturing practices), ICH guidelines, quality by design, and label accuracy. The hosts emphasize how these regulations ensure drug safety and efficacy while addressing the unique challenges of developing cannabis and psychedelic medicines. The discussion delves into the FDA's role in protecting public health, the importance of standardization, and the broader societal impact of bringing these controversial substances into mainstream medicine.
S4 · E1
Jan 31, 2025
20:41

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 1 FDA Drug Development Overview

This podcast episode provides a comprehensive overview of the FDA drug development process for cannabinoid and psychedelic therapeutics. The hosts discuss the journey from pre-clinical research through post-marketing surveillance, explaining key stages including: - Pre-clinical research and molecular interactions with brain receptors - The IND (Investigational New Drug) application process - The three phases of clinical trials and their purposes - Special challenges related to Schedule I substances and regulatory hurdles The conversation also explores broader implications for mental health treatment and addiction, emphasizing how these emerging therapies could reshape our understanding of healing and consciousness.
S4 · E2
Jan 31, 2025
14:23

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 2 Introduction to ICH Guidelines

This podcast episode provides a comprehensive overview of ICH (International Council for Harmonization) guidelines and their application to cannabinoid and psychedelic drug development. The discussion covers the fundamental aspects of ICH guidelines, including: - The Q series focusing on Good Manufacturing Practices (GMP) and quality control - Safety (S) and Efficacy (E) modules for ensuring drug safety and effectiveness through clinical trials - Special challenges in applying these guidelines to cannabinoids and psychedelics, including plant material variability and historical stigma The episode emphasizes how these guidelines help standardize pharmaceutical development globally while ensuring patient safety and product consistency.
S4 · E3
Jan 31, 2025
24:20

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 3 Phase-Appropriate Drug Development

This podcast episode explores phase-appropriate drug development, detailing how testing and validation requirements evolve from early to late-stage clinical trials. It covers the progression from Phase 1's initial safety focus and limited process validation to Phase 2's more comprehensive analytical testing and critical process parameters. The discussion emphasizes how Phase 3 requires rigorous process validation and fully validated analytical methods to ensure consistent, large-scale manufacturing. Throughout the episode, special attention is given to synthetic cannabinoids and psychedelics, highlighting the importance of purity and careful control strategies for these potent substances.
S4 · E4
Jan 31, 2025
15:06

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 4 Quality by Design (QbD) – Fundamentals

This podcast episode explores Quality by Design (QbD) principles in pharmaceutical development, with a special focus on cannabinoid and psychedelic drug manufacturing. The discussion covers the three cornerstone ICH guidelines (Q8, Q9, Q10) and how they enable building quality into medicines from the start rather than just testing final products. The episode delves into practical applications through case studies of companies using QbD for both synthetic compounds and natural extracts, highlighting how advanced technologies like Process Analytical Technology (PAT) and Design of Experiments (DOE) help ensure consistent product quality. The conversation concludes with insights into QbD's role in the future of personalized medicine and 3D-printed drug formulations.
S4 · E5
Jan 31, 2025
18:08

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 4 Quality by Design (QbD) – Fundamentals SUPPLEMENT

This podcast episode explores the fundamental differences between synthetic single-molecule compounds and natural extracts in the context of cannabinoids and psychedelics. The discussion delves into the complexities and challenges of working with natural extracts, including concepts like residual complexity, batch variability, cultivar stability, and polypharmacy. The episode then introduces Quality by Design (QBD) as a systematic approach to managing these challenges, explaining how this scientific methodology helps create more consistent and reliable products. The conversation concludes with insights into personalized medicine and the future potential of these compounds in therapeutic applications.
S4 · E6
Jan 31, 2025
20:11

30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 5 Identifying CQAs and CPPs

This podcast episode explores Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) in the manufacturing of botanical and psychedelic products. The discussion covers key aspects of product quality including potency, purity, safety, and stability. The episode delves into the complexities of extraction processes, including solvent choice and temperature control, while explaining how design space functions as a framework for ensuring consistent product quality through careful control of manufacturing parameters. The conversation also covers formulation challenges, packaging considerations, and the importance of proper storage and labeling in maintaining product integrity.
S4 · E7
Jan 31, 2025
15:39
13 of 26